CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate
- Study conducted in Peru and Panama
- Trial involves 690 participants, including older adults
- Evaluation of safety, reactogenicity and immunogenicity
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicinesbased on messenger ribonucleic acid (“mRNA”), announced today that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV. The dose-confirmation study, entitled CV-NCOV-002, is being conducted in Peru and Panama and will enroll a total of 690 healthy participants in two distinct groups: older adults ages 61 and above, and younger participants 18 to 60 years old.